RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-16.09%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$1.65B
AUM Growth
+$1.65B
(-39%)
Cap. Flow
-$554M
Cap. Flow
% of AUM
-33.52%
Top 10 Holdings %
Top 10 Hldgs %
45.81%
Holding
77
New
–
Increased
9
Reduced
35
Closed
14
Top Buys
| 1 |
Replimune Group
REPL
|
$16.5M |
| 2 |
Cogent Biosciences
COGT
|
$7.06M |
| 3 |
Intuitive Surgical
ISRG
|
$4.58M |
| 4 |
Annexon
ANNX
|
$4.53M |
| 5 |
Establishment Labs
ESTA
|
$4.48M |
Top Sells
| 1 |
Krystal Biotech
KRYS
|
$89.5M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$83.3M |
| 3 |
Atara Biotherapeutics
ATRA
|
$74.9M |
| 4 |
Abbott
ABT
|
$29.8M |
| 5 |
Align Technology
ALGN
|
$28.6M |
Sector Composition
| 1 | Healthcare | 99.13% |
| 2 | Industrials | 0.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Krystal Biotech
KRYS
$4.27B
| $188M | 11.34% | 1,021,078 -487,172 | -32% | -$89.5M |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $105M | 6.35% | 10,595,089 -2,662,197 | -20% | -$26.4M |
|
3
Nurix Therapeutics
NRIX
$714M
| $92.3M | 5.58% | 4,423,616 -59,400 | -1% | -$1.24M |
|
4
Stoke Therapeutics
STOK
$1.08B
| $63.8M | 3.86% | 4,721,054 -351,995 | -7% | -$4.76M |
|
5
Immunome
IMNM
$828M
| $59.2M | 3.58% | 4,889,554 | – | – |
|
6
Regenxbio
RGNX
$451M
| $53.5M | 3.23% | 4,569,802 +18,246 | +0.4% | +$213K |
|
7
LivaNova
LIVN
$3.08B
| $51M | 3.08% | 929,506 -108,274 | -10% | -$5.94M |
|
|
8
Replimune Group
REPL
$422M
| $50.1M | 3.03% | 5,562,096 +1,832,113 | +49% | +$16.5M |
|
9
ADC Therapeutics
ADCT
$345M
| $48.3M | 2.92% | 15,269,217 | – | – |
|
10
Kymera Therapeutics
KYMR
$2.95B
| $47.1M | 2.85% | 1,579,275 -154,814 | -9% | -$4.62M |
|
11
Scholar Rock
SRRK
$3.14B
| $45.4M | 2.75% | 5,453,083 -966,527 | -15% | -$8.05M |
|
12
Zymeworks
ZYME
$1.12B
| $44.3M | 2.68% | 5,211,037 -349,761 | -6% | -$2.98M |
|
13
Fate Therapeutics
FATE
$120M
| $43.2M | 2.61% | 13,169,057 | – | – |
|
|
14
Cogent Biosciences
COGT
$1.69B
| $40.5M | 2.45% | 4,799,973 +837,371 | +21% | +$7.06M |
|
15
Beam Therapeutics
BEAM
$1.66B
| $39.9M | 2.41% | 1,703,061 -176,556 | -9% | -$4.14M |
|
|
SLN
16
Silence Therapeutics
SLN
$227M
| $38.3M | 2.31% | 2,014,296 -13,373 | -0.7% | -$254K |
|
17
Akero Therapeutics
AKRO
$3.74B
| $37.9M | 2.29% | 1,614,473 -244,229 | -13% | -$5.73M |
|
18
Biohaven
BHVN
$1.63B
| $37.7M | 2.28% | 1,087,576 -75,665 | -7% | -$2.63M |
|
19
Neurogene
NGNE
$264M
| $36.9M | 2.23% | 1,013,663 +78,411 | +8% | +$2.85M |
|
20
Pliant Therapeutics
PLRX
$101M
| $34.5M | 2.09% | 3,209,591 +112,371 | +4% | +$1.21M |
|
|
CTLT
21
DELISTED
CATALENT, INC.
CTLT
| $33.5M | 2.02% | 595,570 -36,894 | -6% | -$2.07M |
|
|
22
Annexon
ANNX
$226M
| $31.5M | 1.9% | 6,427,462 +924,272 | +17% | +$4.53M |
|
23
Boston Scientific
BSX
$156B
| $30.1M | 1.82% | 390,253 -170,673 | -30% | -$13.1M |
|
24
IDEAYA Biosciences
IDYA
$2.15B
| $26.7M | 1.61% | 759,516 -163,162 | -18% | -$5.73M |
|
25
Celldex Therapeutics
CLDX
$1.47B
| $26.6M | 1.61% | 718,723 -177,731 | -20% | -$6.58M |
|